Pneumococcal Disease
📧 Sign up to get email alerts when something new happens for Pneumococcal Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age [Phase 3]
Phase 3 trial update evaluating lot-to-lot consistency of a 21-valent pneumococcal conjugate vaccine in healthy infants starting at 2 months…
-
CLINICAL_TRIALS other · 2026-04-22Clinical Trial Update: Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age [Phase 3]
This document provides an update on a Phase 3 trial evaluating a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy inf…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age [Phase 3]
This clinical trial update describes a Phase 3 safety study of a 21-valent pneumococcal conjugate vaccine in healthy infants starting at abo…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: A Study to Learn About How a New Pneumococcal Vaccine Works in Adults [Phase 1]
Pfizer is conducting a Phase 1 clinical trial to study how a new pneumococcal vaccine behaves in adults.
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age [Phase 3]
Phase 3 lot-to-lot consistency study evaluating a 21-valent pneumococcal conjugate vaccine in healthy infants starting at 2 months of age. T…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age [Phase 3]
Phase 3 study evaluating the safety, tolerability, and immunogenicity of VAX-31 with an influenza vaccine in adults 50 years and older; the …
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 [Phase 3]
Phase 3 trial update on safety, tolerability, and immunogenicity of VAX-31 in adults ≥50 with immunobridging to 18-49; the study is currentl…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination [Phase 3]
Phase 3 clinical trial evaluating the safety, tolerability, and immunogenicity of the pneumococcal vaccine VAX-31 in adults 50 and older wit…
-
CLINICAL_TRIALS trial_result · 2026-03-17Clinical Trial Update: Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine [Phase 2]
Phase 2 dose-ranging study evaluating a 25-valent pneumococcal conjugate vaccine has completed, with results posted.
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines [Phase 4]
A Phase 4 clinical trial at the University of Alabama at Birmingham is studying whether pneumococcal conjugate vaccines induce cross-protect…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant [Phase 1]
Phase 1 study evaluating the safety of the 20-valent pneumococcal conjugate vaccine in healthy Chinese adults, children, and infants.
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market
A study is being conducted in Korea to learn more about the use and safety of Prevnar 20 (pneumococcal 20-valent conjugate vaccine) in the m…
-
CLINICAL_TRIALS trial_result · 2026-03-12Clinical Trial Update: A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months
Pfizer's Prevnar 20 pneumococcal vaccine is being studied for safety in infants aged 2 to 6 months, and the trial is currently active but no…
-
CLINICAL_TRIALS trial_result · 2026-03-11Clinical Trial Update: A Study to Learn About How a New Pneumococcal Vaccine Works in Children [Phase 2]
Pfizer completed a Phase 2 trial in children evaluating a new pneumococcal vaccine.
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age [Phase 3]
Sanofi is evaluating a 21-valent pneumococcal conjugate vaccine (PCV21) in healthy infants starting around 2 months of age in a Phase 3 tria…
-
CLINICAL_TRIALS trial_result · 2026-02-25Clinical Trial Update: A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults [Phase 1]
Pfizer completed a Phase 1 study evaluating the safety and potential efficacy of 20vPnC and 13vPnC pneumococcal vaccines in Chinese adults.
-
CLINICAL_TRIALS trial_result · 2026-02-10Clinical Trial Update: Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants [Phase 3]
Phase 3 safety and immunogenicity study of co-administering GSK Meningococcal Group B Vaccine with a 13-valent pneumococcal vaccine and rout…
-
CLINICAL_TRIALS trial_result · 2026-01-28Clinical Trial Update: A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine [Phase 1]
This is a Phase 1b clinical trial evaluating the safety and immunogenicity of a 13-valent pneumococcal polysaccharide conjugate vaccine (PCV…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine [Phase 3]
A Phase 3 clinical trial evaluating a 13-valent pneumococcal conjugate vaccine is currently recruiting, sponsored by Sinovac Life Sciences.
-
CLINICAL_TRIALS trial_result · 2026-01-28Clinical Trial Update: Clinical Trial of PCV24 in Children Aged 2-17 Years [Phase 1]
Phase 1 trial of PCV24 in children aged 2-17 years has completed, assessing safety and initial dosing for pneumococcal disease. The study is…
-
CLINICAL_TRIALS research · 2026-01-26Clinical Trial Update: A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants [Phase 2]
A Phase 2 clinical study to evaluate the safety, tolerability, and immunogenicity of the VAX-31 pneumococcal vaccine in healthy infants, wit…
-
CLINICAL_TRIALS research · 2026-01-16Clinical Trial Update: PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months [Phase 2]
Ongoing Phase 2 clinical trial evaluating the safety and immunogenicity of the PCV24 pneumococcal conjugate vaccine in infants and young chi…
-
CLINICAL_TRIALS trial_result · 2025-12-26Clinical Trial Update: Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years [Phase 1]
Phase I study of the pneumococcal conjugate vaccine PCV24 in children aged 2 months to 17 years is listed as active but not recruiting, spon…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Opportunistic Pneumococcal Immunisation Trial in MALnutrition [Phase 4]
Phase 4 clinical trial to assess opportunistic pneumococcal immunisation in children with severe acute malnutrition. The trial status is NOT…
-
CLINICAL_TRIALS trial_result · 2025-12-17Clinical Trial Update: Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine [Phase 2]
Phase II trial of a 24-valent pneumococcal polysaccharide-conjugate vaccine is underway, with the study currently active but not recruiting.